Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06644326 · ClinicalTrials.gov registry record · Phase 1
A PK Study of IkT-148009 in Older and Elderly Healthy Subjects
A Phase 1 study, sponsored by ABLi Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06644326: Completed Phase 1 study, sponsored by ABLi Therapeutics.
NCT06644326 is a Phase 1 study that has completed, run by ABLi Therapeutics. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06644326, a Phase 1 study, has completed, sponsored by ABLi Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a two-part study. Part A consists of two different IkT-148009-201 solid dosage formulations that are being evaluated to determine their steady-state pharmacokinetic profile. Part B is a drug-drug interaction (DDI) study focused on evaluating the impact of a strong CYP3A inhibitor on the preferred dosage determined in part A.
Primary Outcome
Changes in vital sign measurements including HR and blood pressure.
Interventions
- DRUG 100mg IkT-148009 Wet
- DRUG 200 mg Itraconazole
- DRUG 100mg IkT-148009 Dry
- DRUG 50mg IkT-148009 Wet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 1 |
What the finished NCT06644326 record still lists
NCT06644326 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 4 interventions - of which 100mg IkT-148009 Wet is the first listed.
NCT06644326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06644326 about?
NCT06644326 is a clinical study titled "A PK Study of IkT-148009 in Older and Elderly Healthy Subjects". This is a two-part study. Part A consists of two different IkT-148009-201 solid dosage formulations that are being evaluated to determine their steady-state pharmacokinetic profile. Part B is a drug-drug interaction (DDI) study focused on evaluating the impact of a strong CYP3A inhibitor on the pre...
What is the current status of trial NCT06644326?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-06-21. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT06644326?
The interventions under investigation include: 100mg IkT-148009 Wet (DRUG), 200 mg Itraconazole (DRUG), 100mg IkT-148009 Dry (DRUG), 50mg IkT-148009 Wet (DRUG).
Who is sponsoring clinical trial NCT06644326?
This trial is sponsored by ABLi Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06644326's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI